MGI 197

Drug Profile

MGI 197

Latest Information Update: 08 Dec 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer MGI Pharma; Nonindustrial source
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic retinopathy

Most Recent Events

  • 08 Dec 1998 Discontinued-Preclinical for Diabetic retinopathy in USA (Unknown route)
  • 04 Sep 1996 Suspended-Preclinical for Diabetic retinopathy in USA (Unknown route)
  • 29 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top